Zivo Bioscience, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OID
Mark E. Strome and affiliated entities acquired 100,000 shares of Zivo Bioscience, Inc. common stock at $2.00 per share.
OID
Zivo Bioscience Director and 10% owner Laith L. Yaldoo acquired 1,543 shares of common stock, increasing his indirect beneficial ownership.
OID
A director and 10% owner of Zivo Bioscience, Mark E. Strome, indirectly acquired additional common stock and warrants through an affiliated entity, Strome Mezzanine Fund II, LP.
OID
Zivo Bioscience Director Laith L. Yaldoo has filed a Form 4 indicating a planned future purchase of 2,434 shares of common stock on February 10, 2026, through HEP Investments LLC.
OID
Zivo Bioscience Director Alison A. Cornell purchased 11,709 shares of common stock at $8.54 per share, increasing her direct beneficial ownership to 279,481 shares.
OID
Zivo Bioscience's President and CEO, John Bernard Payne, acquired 11,709 shares of common stock at $8.54 per share, increasing his direct beneficial ownership.
OID
Zivo Bioscience Director and 10% owner Christopher D. Maggiore purchased 1,766 shares of common stock at $8.49 per share.
OID
Zivo Bioscience Director and 10% owner Laith L. Yaldoo acquired 1,766 shares of common stock for $8.49 per share, increasing his indirect beneficial ownership.
OID
Laith L. Yaldoo, a Director and 10% Owner of Zivo Bioscience, Inc., acquired 2,777 shares of common stock at $9 per share.
OID
Mark E. Strome, a Director and 10% owner of Zivo Bioscience, Inc., acquired 20,259 shares of common stock and 2,025 warrants through an affiliated entity.
OID
Zivo Bioscience Director and 10% owner Laith L. Yaldoo acquired 1,659 shares of common stock at $12.05 per share.
OID
Zivo Bioscience Director Christopher D. Maggiore acquired 23,682 shares of common stock and corrected a previous administrative error in his beneficial ownership.
OID
Zivo Bioscience director and 10% owner Laith L. Yaldoo acquired 926 nonstatutory stock options in lieu of retainer fees.
OID
Christopher D. Maggiore, a Director and 10% owner of Zivo Bioscience, Inc., acquired 1,075 nonstatutory stock options as part of his compensation.
OID
Zivo Bioscience Director Alison Cornell acquired 1,223 nonstatutory stock options as part of her compensation.
OID
Zivo Bioscience Director and 10% owner Laith L. Yaldoo acquired 15,322 shares of common stock at $15.99 per share.
OID
Form 4: Zivo Bioscience Director and 10% Owner Increases Stake with Significant Stock and Warrant Purchase
Laith L. Yaldoo, a Director and 10% Owner of Zivo Bioscience, Inc., has increased his beneficial ownership through the purchase of common stock and warrants totaling over $50,000.
OID
Christopher D. Maggiore, a director and 10% owner of Zivo Bioscience, Inc., sold 20 shares of common stock at a price of $16.25 on April 8, 2025.
OID
Laith L. Yaldoo, a director and 10% owner of Zivo Bioscience, Inc., acquired shares in exchange for the release of certain company obligations.
OID
Mark E. Strome, a director and significant shareholder of Zivo Bioscience, acquired 34,000 shares through an exchange agreement, increasing his indirect holdings to 432,683 shares.
OID
Director and 10% owner Laith L. Yaldoo reports acquiring additional shares of Zivo Bioscience, Inc. common stock through non-cash transactions.
OID
Director Christopher D. Maggiore reports acquiring shares of Zivo Bioscience, Inc. on January 1, 2025.
OID
Director Nola E. Masterson reports acquiring additional shares of Zivo Bioscience common stock on January 1, 2025.
OID
Director Alison Cornell of Zivo Bioscience, Inc. reported acquiring 9,797 shares of common stock on January 1, 2025.
OID
Director Mark Strome, through related entities, acquired 75,000 shares and 7,500 warrants of Zivo Bioscience at $20.19 per share.
OID
Director Laith Yaldoo reports acquisition of Zivo Bioscience shares and warrants through an entity.
OID
Zivo Bioscience's CEO, John Bernard Payne, purchased common stock and warrants in the company on October 16, 2024.
OID
Director Alison Cornell purchased 11,990 shares of Zivo Bioscience and related warrants at $8.34 per share on August 22, 2024.
OID
Director Christopher D. Maggiore reports purchasing shares and warrants of Zivo Bioscience, Inc. on August 22, 2024.
OID
Director Christopher D. Maggiore increases his holdings in Zivo Bioscience through the purchase of common stock and common stock purchase warrants.